ALXN2050-MG-201
(2026)Objective
Evaluate efficacy and safety of vemircopan, an oral factor D inhibitor targeting the complement alternative pathway, in adults with AChR-Ab+ generalized myasthenia gravis.
Study Summary
• No significant differences on any secondary endpoint (MG-ADL, QMG, Neuro-QoL Fatigue) at week 8
• Unusually large placebo response (64% vs ~25% expected) likely contributed to failure
• Trial terminated early for lack of efficacy; 1 death from hepatic failure (CMV reactivation) and 1 herpes simplex meningitis (grade 3, treatment-related) in vemircopan arms
Intervention
Oral vemircopan (ALXN2050) 180 mg or 120 mg twice daily — selective factor D inhibitor blocking complement alternative pathway
Inclusion Criteria
Adults ≥18 years with AChR-Ab+ generalized MG diagnosed ≥90 days before screening; MGFA class II–IV; MG-ADL total score ≥5 (with ≥50% from non-ocular items); meningococcal vaccination within 3 years
Study Design
Arms: Vemircopan 180 mg BID vs Vemircopan 120 mg BID vs Placebo (randomized 2:1:2)
Patients per Arm: 180 mg: 28; 120 mg: 14; Placebo: 28 (total N=70)
Outcome
• Week 8 LSM MG-ADL change vs placebo: +0.7 (180 mg, P=.31) and −0.5 (120 mg, P=.54) — NOT significant
• Week 8 LSM QMG change vs placebo: +0.3 (180 mg, P=.78) and −1.6 (120 mg, P=.19) — NOT significant
• AP hemolytic activity reduced >90% at 2h post-dose; sustained pre-dose at week 8 only with 180 mg
• Safety: 1 herpes simplex meningitis (grade 3, treatment-related, 180 mg); 1 death from hepatic failure with CMV reactivation; no meningococcal infections
Clinical Question
In adults with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis, does oral vemircopan (a factor D inhibitor targeting the complement alternative pathway) improve clinical outcomes compared with placebo?
Bottom Line
Vemircopan, an oral factor D inhibitor, did NOT improve MG-ADL or other efficacy endpoints versus placebo in AChR-Ab+ generalized MG, and the phase 2 trial was terminated early for lack of efficacy despite achieving >90% inhibition of the alternative complement pathway.
Major Points
- Primary endpoint (≥2-point MG-ADL reduction for 4 consecutive weeks without rescue therapy) was not met: 57% (180 mg), 57% (120 mg), 64% (placebo); difference −7.1% for both doses (P=.68 and P=.73).
- All secondary endpoints (MG-ADL, QMG, Neuro-QoL Fatigue change from baseline at week 8) were also non-significant.
- Unexpectedly high placebo response (~64% vs anticipated ~25%) may have masked drug effect; MG-ADL is a subjective, patient-reported outcome and placebo response has been rising across recent MG trials.
- Pharmacodynamics confirmed target engagement: AP hemolytic activity reduced to <10% at 2h post-dose in both arms; sustained pre-dose at week 8 only in the 180-mg arm.
- Safety signals of concern: 1 grade 3 herpes simplex meningitis (treatment-related, 180 mg) — unusual for alternative-pathway inhibitors; 1 death from acute necrotic-hemorrhagic hepatic disease with CMV reactivation on chronic hepatic CMV; no meningococcal infections.
- Trial terminated early (February 21, 2024) after the prespecified week 8 primary analysis showed no efficacy. Selective AP inhibition in AChR-Ab+ gMG requires further study.
Study Design
- Study Type
- Phase 2 Randomized Controlled Trial (proof-of-concept, dose-finding)
- Randomization
- Yes
- Blinding
- Double-blind, placebo-controlled, parallel-group
- Sample Size
- 70
- Follow-up
- 8-week primary evaluation period, 26-week extended treatment period, open-label extension up to ~1.5 years (terminated early Feb 21, 2024)
- Centers
- 60
- Countries
- Canada, Germany, Italy, South Korea, Serbia, Spain, Taiwan, USA
Primary Outcome
Definition: Proportion of participants achieving ≥2-point reduction in MG-ADL total score from baseline in any 4 consecutive weeks during the 8-week PEP, without use of rescue therapy
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| - | - | - | - |
Limitations & Criticisms
- Small sample size (N=70) with 2:1:2 randomization limited statistical power and precluded stratification by key baseline variables.
- Substantial baseline imbalances between arms (sex, age at diagnosis, MG duration, MG exacerbation/crisis rates, corticosteroid use) may have biased results toward placebo response.
- Unexpectedly high placebo response (64% vs anticipated ~25%) — attributed to subjective MG-ADL scale, frequent (weekly) assessments, oral BID novelty, and rising placebo response across recent MG trials — may have masked true drug effect.
- Short 8-week primary evaluation period may have been insufficient to detect efficacy of complement modulation.
- Novel herpes simplex meningitis signal (not seen with other AP inhibitors) and a treatment-related fatal hepatic failure (CMV reactivation) raise safety concerns despite absence of meningococcal infections.
- Trial terminated early, limiting long-term safety and durability data.
Citation
JAMA Neurol. 2026;83(6):544-553